Literature DB >> 3900182

Clonidine benefits children with attention deficit disorder and hyperactivity: report of a double-blind placebo-crossover therapeutic trial.

R D Hunt, R B Minderaa, D J Cohen.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3900182     DOI: 10.1016/s0002-7138(09)60065-0

Source DB:  PubMed          Journal:  J Am Acad Child Psychiatry        ISSN: 0002-7138


× No keyword cloud information.
  29 in total

Review 1.  Non-stimulant treatments for ADHD.

Authors:  J Biederman; T Spencer
Journal:  Eur Child Adolesc Psychiatry       Date:  2000       Impact factor: 4.785

Review 2.  The use of α-2A adrenergic agonists for the treatment of attention-deficit/hyperactivity disorder.

Authors:  Amy F T Arnsten
Journal:  Expert Rev Neurother       Date:  2010-10       Impact factor: 4.618

3.  Clonidine extended-release in attention-deficit hyperactivity disorder: profile report.

Authors:  Jamie D Croxtall
Journal:  CNS Drugs       Date:  2012-03-01       Impact factor: 5.749

Review 4.  Adrenergic pharmacology and cognition: focus on the prefrontal cortex.

Authors:  Brian P Ramos; Amy F T Arnsten
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

Review 5.  Psychostimulants as cognitive enhancers: the prefrontal cortex, catecholamines, and attention-deficit/hyperactivity disorder.

Authors:  Craig W Berridge; David M Devilbiss
Journal:  Biol Psychiatry       Date:  2010-09-26       Impact factor: 13.382

Review 6.  Clonidine extended-release: in attention-deficit hyperactivity disorder.

Authors:  Jamie D Croxtall
Journal:  Paediatr Drugs       Date:  2011-10-01       Impact factor: 3.022

Review 7.  Current drug therapy recommendations for the treatment of attention deficit hyperactivity disorder.

Authors:  M Cyr; C S Brown
Journal:  Drugs       Date:  1998-08       Impact factor: 9.546

Review 8.  The cognition-enhancing effects of psychostimulants involve direct action in the prefrontal cortex.

Authors:  Robert C Spencer; David M Devilbiss; Craig W Berridge
Journal:  Biol Psychiatry       Date:  2014-09-28       Impact factor: 13.382

Review 9.  Neuropsychiatric symptoms of fragile X syndrome: pathophysiology and pharmacotherapy.

Authors:  John A Tsiouris; W Ted Brown
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

10.  Alpha-2 adrenergic agonists decrease distractibility in aged monkeys performing the delayed response task.

Authors:  A F Arnsten; T A Contant
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.